MarketCap
Facebook
X
Telegram
Nuvation Bio Gross Profit | NUVB
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Nuvation Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 795 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 795 K | 795 K | 795 K |
Quarterly Gross Profit Nuvation Bio
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 9.77 M | 2.26 M | 990 K | - | -788 K | 88 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.77 M | -788 K | 2.46 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acasti Pharma
ACST
|
-32.3 K | - | 4.01 % | $ 150 M |  Canada |
 |
ADiTx Therapeutics
ADTX
|
268 | - | - | $ 374 |  USA |
 |
Aeterna Zentaris
AEZS
|
2.65 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | USA |
 |
AstraZeneca PLC
AZN
|
48.1 B | - | - | $ 96.9 B |  Britain |
 |
BeiGene, Ltd.
BGNE
|
4.67 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
ChromaDex Corporation
CDXC
|
83.2 M | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
4.15 M | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
5.88 K | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.94 M | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
71.7 K | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
200 K | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
37.5 K | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
225 M | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
-22 K | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
510 K | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
255 M | - | - | $ 889 M | USA |
 |
Amicus Therapeutics
FOLD
|
561 M | - | - | $ 4.47 B | USA |
|
Frequency Therapeutics
FREQ
|
37 M | - | - | $ 528 M | USA |
 |
GlycoMimetics
GLYC
|
20.1 M | - | 9357.83 % | $ 1.01 B | USA |
 |
Happiness Biotech Group Limited
HAPP
|
2.41 M | - | 1.35 % | $ 17.8 M |  China |
 |
KemPharm
KMPH
|
9.89 M | - | -0.34 % | $ 200 M | USA |
 |
NovaBay Pharmaceuticals
NBY
|
6.48 M | - | - | $ 11.3 M | USA |
 |
OncoCyte Corporation
OCX
|
2.3 M | - | 17.22 % | $ 355 K | USA |
 |
Onconova Therapeutics
ONTX
|
231 K | - | -0.47 % | $ 21 M | USA |